By Christie Smythe ( January 8, 2010, 2:06 PM EST) -- Bolstering its bid for permission to market a generic version of allergy treatment Xyzal, Synthon Pharmaceuticals Inc. is claiming that Sepracor Inc. misled the U.S. Patent and Trademark Office when it sought a patent for the active ingredient in the drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.